Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study.

PURPOSE Because individual tumors are heterogeneous, including for (18)F-deoxyglucose (FDG) uptake and, most likely, for radioresistance, selective boosting of high FDG uptake zones within the tumor has been suggested. To do this, it is critical to know whether the location of these high FDG uptake patterns within the tumor remain stable during radiotherapy (RT). METHODS AND MATERIALS Twenty-three patients with Stage I-III non-small-cell lung cancer underwent repeated FDG positron emission tomography computed tomography scans before radical RT (Day 0) and at Days 7 and 14 of RT. On all scans, the high and low FDG uptake regions were autodelineated using several standardized uptake value thresholds, varying from 34% to 80% of the maximal standardized uptake value. The volumes and overlap fractions of these delineations were calculated to demonstrate the stability of the high FDG uptake regions during RT. RESULTS The mean overlap fraction of the 34% uptake zones at Day 0 with Days 7 and 14 was 82.8% +/- 8.1% and 84.3% +/- 7.6%, respectively. The mean overlap fraction of the high uptake zones (60%) was 72.3% +/- 15.0% and 71.3% +/- 19.7% at Day 0 with Days 7 and 14, respectively. The volumes of the thresholds varied markedly (e.g., at Day 0, the volume of the 60% zone was 16.8 +/- 20.3 cm(3)). In contrast, although the location of the high FDG uptake patterns within the tumor during RT remained stable, the delineated volumes varied markedly. CONCLUSION The location of the low and high FDG uptake areas within the tumor remained stable during RT. This knowledge may enable selective boosting of high FDG uptake areas within the tumor.

[1]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Lambin,et al.  Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients , 2007 .

[3]  M Alber,et al.  On biologically conformal boost dose optimization. , 2003, Physics in medicine and biology.

[4]  Sigrid Stroobants,et al.  The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .

[5]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C C Ling,et al.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.

[7]  Philippe Lambin,et al.  PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. , 2007, International journal of radiation oncology, biology, physics.

[8]  J. Daurès,et al.  Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Nagara Tamaki,et al.  Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  J. Bradley A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. , 2005, Seminars in oncology.

[11]  A H Baydush,et al.  Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. , 2004, Medical physics.

[12]  Cedric Yu,et al.  Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[13]  J P Logue,et al.  Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Philippe Lambin,et al.  Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. , 2006, International journal of radiation oncology, biology, physics.

[15]  Søren M Bentzen,et al.  Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.

[16]  D. Abbott,et al.  Functional imaging of intratumoral hypoxia. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[17]  Jean-François Daisne,et al.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.

[18]  H. Dittmann,et al.  Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European journal of nuclear medicine and molecular imaging.

[19]  Leen Paelinck,et al.  The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Morand Piert,et al.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J. García-Segura,et al.  In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. , 1999, Magnetic resonance imaging.

[22]  P. Lambin,et al.  HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[23]  S Mutic,et al.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[24]  H. Dittmann,et al.  Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Søren M Bentzen,et al.  Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  Joos V Lebesque,et al.  Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. , 2005, European journal of cancer.

[27]  Philippe Lambin,et al.  The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. , 2007, European journal of cancer.

[28]  A. Boyer,et al.  Inverse planning for functional image-guided intensity-modulated radiation therapy. , 2002, Physics in medicine and biology.

[29]  L. Dubois,et al.  Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry , 2004, British Journal of Cancer.

[30]  S. Apisarnthanarax,et al.  Current Imaging Paradigms in Radiation Oncology , 2005, Radiation research.

[31]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[32]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Anne Bol,et al.  Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  Ladislav Pecen,et al.  Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. , 2004, Lung cancer.

[35]  Suresh Senan,et al.  Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.